Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel cell- and exosome-based therapies. The company applies proprietary protocols to isolate and process mesenchymal stem cells (MSCs) and their derived extracellular vesicles from human placental and umbilical tissue. Leveraging its platform technology, Organicell aims to address a range of inflammatory, degenerative and immune-mediated conditions through off-the-shelf, allogeneic treatment candidates.
The company’s lead asset, Ryoncil (remestemcel-L), is an MSC-based therapy being evaluated for acute respiratory distress syndrome (ARDS) and other inflammatory indications. In parallel, Organicell is advancing exosome formulations intended to deliver the regenerative and anti-inflammatory benefits of stem cells without the cells themselves. These exosome products are under preclinical and early clinical investigation for applications in orthopedic, pulmonary and dermatological disorders. The diversified pipeline reflects Organicell’s strategy to pursue multiple indications with high unmet medical need.
Organicell operates a network of development and manufacturing facilities in the United States, including its GMP-certified manufacturing site in Perrysburg, Ohio. The company also maintains strategic partnerships and research collaborations in Mexico and Europe to expand access to its therapies and conduct clinical trials. Organicell’s integrated approach spans tissue sourcing, product development and regulatory pathways, positioning the company to advance its candidates through clinical milestones.
Founded in 2005 as a pioneer in regenerative medicine, Organicell has evolved from early research on perinatal tissue into a clinical-stage organization. Under the leadership of President and Chief Executive Officer Elliott J. Lander, Ph.D., the company continues to build a proprietary portfolio of cell-derived therapeutics. Organicell’s management team brings extensive experience in biotechnology, manufacturing and regulatory affairs, guiding its mission to deliver transformative treatments for patients with limited therapeutic options.
AI Generated. May Contain Errors.
